CClinicalTrials.gg
CompletedNCT01764516Updated Jan 9, 2013

Study on Serum Zinc and Selenium Levels in Epileptic Patients

An observational study in Generalized Epileptic, sponsored by Arak University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-09.

Sponsored by Arak University of Medical Sciences · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.

Read the detailed description

Forty patients aged 18 to 50 years visiting Vali-Asr hospital in Arak, I.R. Iran, who were diagnosed with generalized form of epilepsy by a neurologist for the first time were recruited as cases. The control group (n=40) was selected from healthy individuals, in whom no disease was diagnosed until this study, and were matched to the case group by age, sex, and economical status.

02

Conditions studied

  • Generalized Epileptic

Browse trials for

Keywords

  • zinc
  • selenium
  • serum
  • epilepsy
  • antioxidants
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

all generalized and single epileptic patiants which were identify for fist time

Inclusion criteria

New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications,

Exclusion criteria

Exclusion Criteria:

presence of above criteria as well as, generalized and single epileptic cases under treatment

04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (actual)
Target follow-up
1 Week
Patient registry
Yes
Biospecimen retention
None retained

Groups and cohorts

  • Zinc level (micro gram per deciliter)

    In all cases

  • Selenium level (micro gram per deciliter)

    In all cases

  • Zinc level in male (micro gram per deciliter)
  • Selenium level in male (micro gram per deciliter)
  • Zinc level in Female (micro gram per decilitre)
  • Selenium level in Female (micro gram per decilitre)
05

What researchers measure

Primary outcomes

  1. Study on Serum Zinc and Selenium Levels in Epileptic Patients

    decrement in serum zinc and selenium level

    Time frame: 5 months

Secondary outcomes

  1. Comparison between the selenium levels by gender in two groups

    Time frame: 5 months

06

Study locations

1 site
  • Vali-Asr Hospital
    Arak, Central province, Iran, Islamic Republic of
07

Registry details

Key details

Study ID
NCT01764516
Lead sponsor
Arak University of Medical Sciences
Responsible party
Dr. Farahani Heidar (faculity of medicine, department of biochemistry, Arak University of Medical Sciences) — Principal investigator
First posted
Jan 9, 2013
Start date
Nov 2011
Primary completion
Mar 2012
Completion
May 2012
Last update
Jan 9, 2013

Study contacts

Heidar N Farahani, PhD
principal investigator · Department of Biochemistry,Arak medical sciences university

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion